Your browser doesn't support javascript.
loading
The Effects of the ManageHF4Life Mobile App on Patients With Chronic Heart Failure: Randomized Controlled Trial.
Dorsch, Michael P; Farris, Karen B; Rowell, Brigid E; Hummel, Scott L; Koelling, Todd M.
Afiliación
  • Dorsch MP; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, United States.
  • Farris KB; Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, United States.
  • Rowell BE; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, United States.
  • Hummel SL; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, United States.
  • Koelling TM; Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, United States.
JMIR Mhealth Uhealth ; 9(12): e26185, 2021 12 07.
Article en En | MEDLINE | ID: mdl-34878990
ABSTRACT

BACKGROUND:

The successful management of heart failure (HF) involves guideline-based medical therapy as well as self-management behavior. As a result, the management of HF is moving toward a proactive real-time technological model of assisting patients with monitoring and self-management.

OBJECTIVE:

The aim of this paper was to evaluate the efficacy of enhanced self-management via a mobile app intervention on health-related quality of life, self-management, and HF readmissions.

METHODS:

A single-center randomized controlled trial was performed. Participants older than 45 years and admitted for acute decompensated HF or recently discharged in the past 4 weeks were included. The intervention group ("app group") used a mobile app, and the intervention prompted daily self-monitoring and promoted self-management. The control group ("no-app group") received usual care. The primary outcome was the change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) score from baseline to 6 and 12 weeks. Secondary outcomes were the Self-Care Heart Failure Index (SCHFI) questionnaire score and recurrent HF admissions.

RESULTS:

A total of 83 participants were enrolled and completed all baseline assessments. Baseline characteristics were similar between the groups except for the prevalence of ischemic HF. The app group had a reduced MLHFQ at 6 weeks (mean 37.5, SD 3.5 vs mean 48.2, SD 3.7; P=.04) but not at 12 weeks (mean 44.2, SD 4 vs mean 45.9, SD 4; P=.78), compared to the no-app group. There was no effect of the app on the SCHFI at 6 or 12 weeks. The time to first HF readmission was not statistically different between the app group and the no-app group (app group 11/42, 26% vs no-app group 12/41, 29%; hazard ratio 0.89, 95% CI 0.39-2.02; P=.78) over 12 weeks.

CONCLUSIONS:

The adaptive mobile app intervention, which focused on promoting self-monitoring and self-management, improved the MLHFQ at 6 weeks but did not sustain its effects at 12 weeks. No effect was seen on HF self-management measured by self-report. Further research is needed to enhance engagement in the app for a longer period and to determine if the app can reduce HF readmissions in a larger study. TRIAL REGISTRATION ClinicalTrials.gov NCT03149510; https//clinicaltrials.gov/ct2/show/NCT03149510.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Aplicaciones Móviles / Insuficiencia Cardíaca Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: JMIR Mhealth Uhealth Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Aplicaciones Móviles / Insuficiencia Cardíaca Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: JMIR Mhealth Uhealth Año: 2021 Tipo del documento: Article